Inission (INISS) Q4 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2024 earnings summary
26 Dec, 2025Executive summary
Q4 sales declined 4% to SEK 531.2 million, with organic sales down 11.9% after adjusting for the AxxE acquisition; order intake for Q4 rose to SEK 761.3 million, reflecting strong recovery despite weak demand.
Q4 EBITDA was SEK 17.8 million, SEK 13.4 million lower year-over-year, and EBITA was SEK 17.8 million, impacted by SEK 4.8 million in one-time costs for the Nasdaq Stockholm main list transfer.
Full-year revenue reached SEK 2.15 billion, with EBITDA at SEK 125 million and EBITA at SEK 124.9 million; organic sales dropped SEK 191 million year-over-year.
Cost reductions are ongoing, especially in fixed costs and overhead, with full effects expected by Q2 2025.
The AXXE AS acquisition contributed SEK 43.3 million to Q4 sales and SEK 146.2 million to full-year sales.
Financial highlights
Q4 net sales were SEK 531.2 million; full-year net sales SEK 2,149.7 million.
Q4 EBITA margin was 3.4%, and full-year EBITA margin was 5.8%, down from 7.4% last year.
Q4 EPS dropped from SEK 0.6 to SEK 0.4; full-year EPS was SEK 3.3.
Book-to-bill ratio reached 1.4 in Q4, indicating strong order intake.
Strong Q4 cash flow from operations at SEK 69.9 million; full-year adjusted cash flow SEK 166 million after COVID loan repayment and factoring changes.
Outlook and guidance
2025 revenue target set at SEK 2.2 billion, with EBITDA margin above 6%.
Market recovery is expected in H2 2025, with improved order intake and more optimistic customer signals.
Full cost savings from efficiency measures are anticipated to materialize in Q2 2025.
Net debt/EBITDA target below 2.5; equity ratio around 30%.
Margin guidance is conservative due to volume uncertainty; improvement expected if demand recovers in H2.
Latest events from Inission
- 2025 revenue rose to SEK 2,206.2 million, with strong cash flow and positive 2026 outlook.INISS
Q4 202520 Feb 2026 - Q2 sales up 1.4% to 570 MSEK, but organic growth and margins declined.INISS
Q2 202423 Jan 2026 - Sales and EBIT fell, but order intake and stability improved; guidance and cost base adjusted.INISS
Q3 202415 Jan 2026 - Revised targets and integration efforts position the company for renewed growth next year.INISS
ABGSC Investor Days11 Jan 2026 - Targeting 15% annual growth and 9% EBITDA margin, leveraging acquisitions and mega trends.INISS
CMD 202529 Nov 2025 - Order intake up, sales and profit down; cost cuts and Nasdaq listing shape cautious outlook.INISS
Q1 & AGM 202526 Nov 2025 - Sales fell 6.2%, but order intake, cash flow, and acquisitions signal H2 recovery.INISS
Q2 202523 Nov 2025 - Q3 sales and margins improved, EMS strong, Enedo restructuring, 2025 targets revised.INISS
Q3 20257 Nov 2025